SIGLEC9 and prostate cancer: In prostate cancer, ST3Gal1 was shown to promote immune evasion by synthesizing α2,3‐sialylated ligands for Siglec‐7 and Siglec‐9 receptors on immunosuppressive macrophages, thereby disrupting anti‐tumor immunity.36